Hydroxychloroquine for COVID-19: A Review

In dealing with the COVID-19 pandemic, hydroxychloroquine (HCQ) as a drug captured serious worldwide attention. Some in-vitro and in-vivo studies recently showing possible inhibition of SARS-CoV-2 by the use of HCQ. At same time, however, a few cases research demonstrating NO medical benefit/ poor clinical result with major adverse effects through the use of HCQ in coronavirus disease-2019 treatment. Therefore, the use of HCQ (in treatment with COVID-19) is of considerable international concern, although a consensus has not yet been reached. Further proof to prove HCQ 's efficacy against COVID-19 is still needed. In view of this, the current analysis illustrates the ongoing work on use of HCQ in the management of coronavirus disease-2019. The present analysis will address the potential in-vitro study of HCQ's anti-viral function, prophylaxis strategy and impact of HCQ on SARS-CoV-2 viruses. This review also sums up and discusses all clinical practice trials / HCQ use research studies against COVID-19 (with clinical results). Finally, considering the public health and pharmacovigilance concerns, possible detrimental effects are also discussed.